NCT04590118 is a Phase 1, PHASE2 clinical trial of it-hMSC in Ischemic Stroke, sponsored by Jiuzhitang Maker (Beijing) Cell Technology Co.,Ltd..

Who is sponsoring NCT04590118?

NCT04590118 is sponsored by Jiuzhitang Maker (Beijing) Cell Technology Co.,Ltd..

What drugs are being tested in NCT04590118?

Interventions in NCT04590118: it-hMSC, Placebo.

What condition does NCT04590118 study?

NCT04590118 studies Ischemic Stroke.

Is NCT04590118 still recruiting?

NCT04590118 is currently status unknown. Last updated 31 March 2022.

Last reviewed 2022-03-31 · How we verify

NCT04590118

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Allogeneic Mesenchymal Stem Cells for the Survivors of Ischemic Stroke Trial (ASSIST)

Status unknown Phase 1, PHASE2 Last updated 31 March 2022

What this trial tests

Phase 1, PHASE2 trial testing it-hMSC in Ischemic Stroke in 60 participants. Status unknown.

Timeline

26 April 2021

Primary endpoint
1 April 2023

1 August 2023

Quick facts

Lead sponsor	Jiuzhitang Maker (Beijing) Cell Technology Co.,Ltd.
Phase	Phase 1, PHASE2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	60
Start date	26 April 2021
Primary completion	1 April 2023
Estimated completion	1 August 2023
Sites	1 location across China

Drugs / interventions tested

it-hMSC — full drug profile →
Placebo

Conditions studied

Ischemic Stroke — all drugs for Ischemic Stroke →

Sponsor

Jiuzhitang Maker (Beijing) Cell Technology Co.,Ltd. — full company profile →

Who can join

18 and older, any sex, with Ischemic Stroke. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of single injection of it-hMSC in patients with ischemic stroke in a multicenter, blind, randomized, placebo controlled trial

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Stem Cell- and Cell-Based Therapies for Ischemic Stroke.
Nistor-Cseppentö DC, Jurcău MC, Jurcău A, Andronie-Cioară FL, et al · · 2022 · cited 17× · PMID 36421118 · DOI 10.3390/bioengineering9110717
Mechanism of inflammatory response and therapeutic effects of stem cells in ischemic stroke: current evidence and future perspectives.
Wang Y, Yuan T, Lyu T, Zhang L, et al · · 2025 · cited 16× · PMID 38767477 · DOI 10.4103/1673-5374.393104
Current Status of Mesenchymal Stem/Stromal Cells for Treatment of Neurological Diseases.
Soares MBP, Gonçalves RGJ, Vasques JF, da Silva-Junior AJ, et al · · 2022 · cited 16× · PMID 35782379 · DOI 10.3389/fnmol.2022.883378
Ischemic Brain Stroke and Mesenchymal Stem Cells: An Overview of Molecular Mechanisms and Therapeutic Potential.
Jingli Y, Jing W, Saeed Y, Saeed Y. · · 2022 · cited 15× · PMID 35663353 · DOI 10.1155/2022/5930244
Mesenchymal stem cell therapy in ischemic stroke trials. A systematic review.
Moñivas Gallego E, Zurita Castillo M. · · 2024 · cited 13× · PMID 38633415 · DOI 10.1016/j.reth.2024.03.026
Treatment of ischemic stroke with modified mesenchymal stem cells.
Chen H, Zhou L. · · 2022 · cited 13× · PMID 35919816 · DOI 10.7150/ijms.74161
How neural stem cell therapy promotes brain repair after stroke.
Weber RZ, Rust R, Tackenberg C. · · 2025 · cited 3× · PMID 40409262 · DOI 10.1016/j.stemcr.2025.102507
Hypoxia and interleukin-1-primed mesenchymal stem/stromal cells as novel therapy for stroke.
Salaudeen MA, Allan S, Pinteaux E. · · 2024 · cited 2× · PMID 37987924 · DOI 10.1007/s13577-023-00997-1

Verify or expand the search:

Other trials of it-hMSC

Trials testing the same drug.

NCT04953663 — Clinical Plan of Ischemic Stroke · Phase 1, PHASE2 · unknown

Other recruiting trials for Ischemic Stroke

Currently open trials in the same condition.

NCT07509645 — Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Post · Phase 3 · recruiting
NCT07375953 — Repeated Intravenous Thrombolysis for Ischemic Stroke Within 3.0 Hours of Onset With Tenecteplase (RITIS-TNK) · Phase 2 · recruiting
NCT07375966 — Repeated Intravenous Thrombolysis for Ischemic Stroke With Medium to Large Vessel Occlusion Presenting Within 4.5 Hours · Phase 2 · recruiting
NCT07491952 — Continuous Dual Aspiration Technique With Zoom System for Stroke · recruiting
NCT07371455 — A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LWP779 in Healthy Participants · Phase 1 · recruiting

Other Jiuzhitang Maker (Beijing) Cell Technology Co.,Ltd. trials

Trials by the same sponsor.

NCT07177677 — A Study of Mesenchymal Stem Cell in the Treatment of Autism Spectrum Disorder · Phase 1 · not yet recruiting
NCT06111846 — Study of Human Bone Marrow Mesenchymal Stem Cells in APAP · Phase 2 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04590118 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Jiuzhitang Maker (Beijing) Cell Technology Co.,Ltd.
Last refreshed: 31 March 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04590118.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing